Dosing & Uses
Dosage Forms & Strengths
capsule
- 123mg
Fabry Disease
Treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene (GLA) variant based on in vitro assay data
123 mg PO once every other day at same time of day
Also see administration
Dosage Modifications
Renal impairment
- Mild to moderate (eGFR ≥30 mL/min/1.73 m²): No dosage adjustment required
- Severe (eGFR<30 mL/min/1.73 m²) or end-stage renal disease: Not recommended
Dosage Considerations
Consultation with a clinical genetics professional is strongly recommended in cases in which amenable GLA variant is of uncertain clinical significance (VUS, variant of uncertain significance) or may be benign (not causing Fabry disease)
Safety and efficacy not established
Interactions
Interaction Checker
No Results

Contraindicated
Serious - Use Alternative
Significant - Monitor Closely
Minor

Contraindicated (0)
Serious - Use Alternative (0)
Monitor Closely (0)
Minor (0)
Adverse Effects
>10%
Headache (35%)
Nasopharyngitis (18%)
Urinary tract infection (15%)
Nausea (12%)
Pyrexia (12%)
1-10%
Abdominal pain (9%)
Back pain (9%)
Cough (9%)
Diarrhea (9%)
Epistaxis (9%)
Warnings
Contraindications
None reported by the manufacturer
Cautions
This porduct was approved under accelerated approval based on reduction in kidney interstitial capillary cell globotriaosylceramide (KIC GL-3) substrate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.
Pregnancy
Pregnancy
Current study collects data on pregnant women with Fabry disease, either exposed or unexposed to GALAFOLD; healthcare providers are encouraged to register patients or obtain additional information by contacting the Pregnancy Coordinating Center at 1-888-239-0758; email fabrypregnancy@ubc.com, or visit www.fabrypregnancyregistry.com
Available data are not sufficient to assess drug-associated risks of major birth defects, miscarriage, or adverse maternal or fetal outcomes; in animal reproduction studies, no adverse developmental effects were observed
Infertility
- Effects on fertility in humans not studied; transient and fully reversible infertility in male rats associated with treatment at systemic exposure (AUC) equivalent to human exposure at recommended dose; complete reversibility was seen at 4 weeks after termination of treatment; drug did not affect fertility in female rats
Lactation
Current study collects data on effects of GALAFOLD on lactation for women with Fabry disease and their neonates and infants up to 1 year of age who are exposed through breast milk; healthcare providers are encouraged to register patients or obtain additional information by contacting Pregnancy Coordinating Center at 1-888-239-0758, email fabrypregnancy@ubc.com, or visit www.fabrypregnancyregistry.com
There are no human data available on the presence of the drug in human milk, the effects on breastfed infant, or on milk production; the drug is present in the milk of lactating rats; when a drug is present in animal milk, it is likely that the drug will be present in human milk; developmental and health benefits of breastfeeding should be considered along with mother’s clinical need for therapy and any potential adverse effects on the breastfed child from drug or from underlying maternal condition
Pregnancy Categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk. C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done. D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk. X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist. NA: Information not available.Pharmacology
Mechanism of Action
Binds to and stabilizes endogenous alpha-galactosidase A (alpha-Gal A) that is made in the patient’s own cells, with the intention of enabling its trafficking from the endoplasmic reticulum to lysosomes (designed to act as a “pharmacological chaperone”); once delivered to lysosomes, the alpha-Gal A enzyme can degrade the accumulated glycolipid (globotriaosylceramide [GL-3]) and globotriaosylsphingosine (lyso-Gb3)
Certain GLA variants (mutations) causing Fabry disease result in production of abnormally folded and less stable forms of alpha-Gal A protein, which, however, retain enzymatic activity; those GLA variants, referred to as amenable variants, produce alpha-Gal A proteins that may be stabilized by migalastat, thereby restoring their trafficking to lysosomes and their intralysosomal activity
Absorption
Absolute bioavailability: ~ 75%
Peak plasma time: 3 hr
Plasma exposure (AUC and Cmax): Showed dose-proportional increases at oral doses from 75-1250 mg (doses from 0.5- to 8.3-fold of approved recommended dosage); drug does not accumulate following administration of drug every other day
Effects of food
- Administration 1 hr before a high-fat (850 calories; 56% from fat) or light meal (507 calories; 30% from fat), or 1 hr after a light meal, reduced the mean migalastat AUC by 37-42% and peak plasma concentration by 15-39% compared to fasting state
Distribution
Apparent volume of distribution (Vz/F): 89 L (range: 77-133 L) at steady state in Fabry patients
Metabolism
Based upon in vivo data, drug is a substrate for uridine diphosphate glucuronosyltransferase (UDPGT), a minor elimination pathway
Elimination
Urine (77%) and feces (20%)
Half-life: 4 hr
Clearance: 12.5 L/hr
Administration
Oral Administration
Take on empty stomach; do not consume food at least 2 hr before and 2 hr after taking drug to give a minimum 4-hr fast; clear liquids can be consumed during this 4-hour period
Not to be taken on 2 consecutive days
Swallow capsules whole; do not cut, crush, or chew
Missed dose
- If dose missed entirely for the day, take missed dose only if within 12 hours of normal time dose should have been taken; if more than 12 hours passed, resume taking drug at next planned dosing day and time, according to every-other-day dosing schedule
Storage
Store at USP controlled room temperature of 20-25°C (68-77°F), with excursions permitted between 15° and 30°C (59° and 86°F)
Images
BRAND | FORM. | UNIT PRICE | PILL IMAGE |
---|---|---|---|
Galafold oral - | 123 mg capsule | ![]() |
Copyright © 2010 First DataBank, Inc.
Formulary
Adding plans allows you to compare formulary status to other drugs in the same class.
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.